Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial.
about
The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpointsClinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated ReviewTrials with 'epigenetic' drugs: an updateCustomized targeted therapy in Hodgkin lymphoma: hype or hope?New and emerging HDAC inhibitors for cancer treatmentHistone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancyPhase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma.ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma.Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin's lymphoma with an emphasis on targeted therapies and transplantation strategiesHodgkin lymphoma: 2014 update on diagnosis, risk-stratification, and management.Ligand Based Pharmacophore Modeling and Virtual Screening Studies to Design Novel HDAC2 Inhibitors.Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents.Successful strategies in the discovery of small-molecule epigenetic modulators with anticancer potential.Challenges and perspective of drug repurposing strategies in early phase clinical trials.An epithelial marker promoter induction screen identifies histone deacetylase inhibitors to restore epithelial differentiation and abolishes anchorage independence growth in cancers.Targeting epigenetic regulations in cancerEpigenetic therapy: use of agents targeting deacetylation and methylation in cancer management.HR23b expression is a potential predictive biomarker for HDAC inhibitor treatment in mesenchymal tumours and is associated with response to vorinostat.Relapsed Hodgkin lymphoma: management strategiesSingle or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group.Impact of the microbial derived short chain fatty acid propionate on host susceptibility to bacterial and fungal infections in vivo.Loss of the proteins Bak and Bax prevents apoptosis mediated by histone deacetylase inhibitors.Inhibition of histone deacetylases induces formation of multipolar spindles and subsequent p53-dependent apoptosis in nasopharyngeal carcinoma cells.From drug discovery to biomarker-driven clinical trials in lymphomaSelective targeting of HDAC1/2 elicits anticancer effects through Gli1 acetylation in preclinical models of SHH Medulloblastoma.Toxicological and metabolic considerations for histone deacetylase inhibitors.Targeting oncogenic and epigenetic survival pathways in lymphoma.CD30 as a therapeutic target for lymphoma.Managing Hodgkin lymphoma relapsing after autologous hematopoietic cell transplantation: a not-so-good cancer after all!Towards selective inhibition of histone deacetylase isoforms: what has been achieved, where we are and what will be next.An update on emerging drugs for Hodgkin lymphoma.Histone deacetylase inhibitors and cell death.Targeting the histone orthography of cancer: drugs for writers, erasers and readers.Recent advances in Hodgkin lymphoma: interim PET and molecular-targeted therapy.Genetic and molecular targets in lymphoma: implications for prognosis and treatment.Current role of autologous and allogeneic stem cell transplantation for relapsed and refractory hodgkin lymphoma.Primary refractory and early-relapsed Hodgkin's lymphoma: strategies for therapeutic targeting based on the tumour microenvironment.Microenvironment-related biomarkers and novel targets in classical Hodgkin's lymphoma.Impact of Histone Deacetylase Inhibitors on microRNA Expression and Cancer Therapy: A Review.Risk-adapted strategies for the treatment of Hodgkin lymphoma.
P2860
Q26745842-3A7F4915-6B38-4CA0-882D-84E533DED9D8Q26770716-0347C11D-171F-4D9C-9772-BB280FA16D03Q27000542-E9530954-578A-40F3-BAAF-A19085C53240Q27002554-A167A7F2-B69B-44E6-B107-CB423F303D92Q27022413-193EDBBA-BFB5-498D-92B6-C10709C271BDQ28082536-4E95CADF-E1B8-46A8-A9D0-0C5132BB313DQ33410761-CB756170-B4DA-4622-BCBD-C64008F9222DQ33432027-55E985CF-370E-47A4-BE2C-57069681D35EQ33886267-D0A30941-1436-40E4-8A26-5E7EF905B8AFQ34662648-3F97AAB4-F0A9-454C-BA21-BBC94703822DQ34695894-3E2CE472-63E1-4840-9BE7-C679CAB83C67Q35214924-4FC8918E-3A42-422E-90E1-8269B908AACDQ35824823-0EF0A877-E633-4B8C-B0C7-3E424DF594CBQ35863063-510B9D90-D8F0-4A8D-A881-77206E1F18C0Q36110047-9B7DD355-458C-4FFC-9E3A-41B5C67F593FQ36398751-79E94FF6-C9B8-4EF3-928B-A1C543FB0A3FQ36738463-E88786F6-67DE-436E-8D60-A166B7824C74Q37002069-7B5C266D-4268-48A0-8D35-491BE702C44CQ37008427-9CC92B99-961D-423B-B8A8-6B0CFDC7C80EQ37216339-F67EEA1C-8EC4-424C-86F4-E3FBBD07117CQ37448992-873AF23E-FB33-4B35-BF38-49B0890B07E3Q37505528-8B3194D7-2DAC-4BEA-BC99-E2EA3D9F45D5Q37536821-3B0FF352-DEC7-48CD-9DA5-70BFCC39D48EQ37551148-6D901C53-ABCA-47AB-93BC-53E43836AD17Q37690128-44DF65E6-9090-4090-BF69-98EC47C7D610Q38071321-FA252BB1-37AE-4A00-8D9C-9B8495979B2EQ38084734-2B58BA06-85F8-41FB-BD04-32817028B32EQ38138482-C7658D08-6369-4466-82C8-866C56206DB5Q38179975-0C92936A-C9BB-4C6E-8DDF-DEBEFB40C096Q38204386-B35BD992-A7D3-4599-9C6D-0EF9BF7D2D19Q38205874-41B26AD6-F372-4E23-8DB9-D08CC670FCB9Q38217666-827EA60A-B160-4888-A897-B76E4CAE06E9Q38231327-0AD8482A-3B9D-4D2E-887A-DF0CE1543651Q38285627-DA711B3C-B18F-49DE-84A7-10CAFA5170D2Q38294626-83B3EAFA-8951-468B-A12E-8E10714D4C46Q38368587-BFA868AE-167C-4E21-8C24-69C54A17D5F1Q38466376-1E072B77-489C-4AED-B808-29F9BA8EA6CEQ38557033-59211541-7606-4C3B-AC65-DD9CFB0A8AD3Q38572855-3F386E61-FE34-40C2-B720-789027FC5441Q38591137-3EAE3FDE-52AD-4343-B92E-392772F41C70
P2860
Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 25 October 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Mocetinostat for relapsed clas ...... el, single-arm, phase 2 trial.
@en
Mocetinostat for relapsed clas ...... el, single-arm, phase 2 trial.
@nl
type
label
Mocetinostat for relapsed clas ...... el, single-arm, phase 2 trial.
@en
Mocetinostat for relapsed clas ...... el, single-arm, phase 2 trial.
@nl
prefLabel
Mocetinostat for relapsed clas ...... el, single-arm, phase 2 trial.
@en
Mocetinostat for relapsed clas ...... el, single-arm, phase 2 trial.
@nl
P2093
P2860
P1433
P1476
Mocetinostat for relapsed clas ...... el, single-arm, phase 2 trial.
@en
P2093
Ahmed Galal
Amanda Copeland
Anas Younes
Daniela Buglio
Jeffrey Besterman
Jessica K Paulus
John Kuruvilla
L Jeffrey Medeiros
M Renee Ward
Michel Drouin
P2860
P304
P356
10.1016/S1470-2045(11)70265-0
P577
2011-10-25T00:00:00Z